GlassScriptPhysician profile
Lisa G Abbott
NPI 1609883701
$129,870.45
in general payments reported to CMS, 2019-2025
70 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $4,607 · 2021: $11K · 2022: $6,206 · 2023: $28K · 2024: $3,915 · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Food and Beverage: $15K · Travel and Lodging: $8,196 · Consulting Fee: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,606.38 |
| Food and Beverage | $14,589.76 |
| Travel and Lodging | $8,196.32 |
| Consulting Fee | $1,904.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $69,975.91 | 2022-2025 | Yorvipath |
| Shire North American Group INC | $9,003.99 | 2019 | |
| Novo Nordisk INC | $7,341.65 | 2019-2025 | Sogroya, Norditropin, Macrilen |
| Abbvie INC. | $6,159.38 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $5,388.88 | 2019-2025 | Korlym |
| Clarus Therapeutics INC. | $4,635.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $2,427.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,249.02 | 2019-2024 | |
| Senseonics, Incorporated | $2,170.00 | 2019-2022 | |
| Lilly USA, LLC | $2,037.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,844.31 | 2019-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $1,651.41 | 2019-2025 | Afrezza |
| Vertex Pharmaceuticals Incorporated | $1,200.00 | 2022 | |
| Horizon Therapeutics Plc | $1,034.18 | 2021-2023 | Tepezza |
| Amarin Pharma, INC. | $982.76 | 2019-2021 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $932.43 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $899.36 | 2019-2025 | |
| Medtronic, INC. | $847.78 | 2021-2025 | Minimed 780g, Simplera Sensor, Minimed 770g |
| Insulet Corporation | $831.45 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $822.26 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $669.20 | 2020-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $639.12 | 2020-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $568.78 | 2019-2025 | Strensiq |
| Radius Health, INC. | $564.15 | 2019-2025 | Tymlos |
| Antares Pharma, INC. | $389.70 | 2019-2025 | Xyosted |
| Abbott Laboratories | $389.23 | 2019-2025 | Freestyle Libre 3, Eterna |
| Neurocrine Biosciences, INC. | $358.88 | 2024-2025 | |
| Dexcom, INC. | $335.24 | 2022-2023 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $282.62 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $266.16 | 2023-2025 | |
| Chiesi USA, INC. | $260.23 | 2024 | Myalept, Mycapssa |
| Grt US Holding, INC. | $215.27 | 2022 | |
| Ibsa Pharma INC. | $210.32 | 2020-2023 | Tirosint, Licart |
| Lexicon Pharmaceuticals, INC. | $172.62 | 2024-2025 | |
| Companion Medical, INC. | $162.95 | 2020 | |
| Amryt Pharma Holdings LTD | $153.90 | 2022-2023 | Myalept |
| Valeritas, INC. | $138.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.59 | 2020-2022 | |
| Gilead Sciences, INC. | $123.70 | 2019 | |
| Merck Sharp & Dohme LLC | $123.24 | 2019-2020 | |
| Soleno Therapeutics, INC. | $119.16 | 2025 | Vykat Xr |
| Almatica Pharma LLC | $117.05 | 2024-2025 | Teriparatide, Loreev Xr |
| Biomarin Pharmaceutical INC. | $110.51 | 2021-2022 | |
| Astellas Pharma US INC | $107.97 | 2023-2025 | Veozah |
| Kyowa Kirin, INC. | $85.25 | 2023-2024 | Crysvita |
| Madrigal Pharmaceuticals | $67.79 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $66.09 | 2021-2022 | |
| Medtronic Minimed, INC. | $57.63 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $47.25 | 2025 | Tlando |
| Regeneron Healthcare Solutions, INC. | $45.90 | 2019 | |
| Ferring Pharmaceuticals INC. | $41.66 | 2019 | |
| Eisai INC. | $39.48 | 2019-2020 | |
| Alfasigma USA, INC. | $34.82 | 2020-2021 | |
| Rhythm Pharmaceuticals, INC. | $33.19 | 2025 | Imcivree |
| Halozyme INC | $28.14 | 2023 | |
| Janssen Scientific Affairs, LLC | $26.77 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.68 | 2021 | |
| Alvogen INC | $26.05 | 2024 | Teriparatide |
| Beta Bionics, INC. | $23.76 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Endo Pharmaceuticals INC. | $23.28 | 2019 | |
| Pfizer INC. | $22.83 | 2022 | |
| Averitas Pharma INC. | $22.46 | 2025 | Qutenza |
| Rgh Enterprises LLC | $20.90 | 2023 | |
| Nevro Corp. | $19.33 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.30 | 2021 | |
| Vistapharm, INC. | $17.91 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.04 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.64 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$45,249.36 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.